MedPath

Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy Compliance in Patients With Acute Coronary Syndromes: a Prospective Randomized Clinical Study

Not Applicable
Completed
Conditions
Acute Coronary Syndrome
Interventions
Behavioral: Motivational Interview
Registration Number
NCT02927808
Lead Sponsor
AHEPA University Hospital
Brief Summary

This study will investigate the impact of motivational interviewing in achieving low-density lipoprotein cholesterol therapeutic targets in patients with acute coronary syndromes.

Detailed Description

To determine whether a strategy of enhanced information about the risks of high plasma low-density lipoprotein cholesterol (LDL-C) and the importance of lipid-lowering medication together with close follow-up and motivational interviewing is superior than usual care in achieving LDL-C therapeutic targets, as set by current practice guidelines (LDL-C \<70 mg/dL or \>50% reduction from baseline LDL-C) in patients with acute coronary syndromes.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
360
Inclusion Criteria
  • Subject hospitalized for acute coronary syndrome (STEMI, NTEMI or unstable angina)
  • Subject currently on lipid-lowering therapy or prescribed lipid-lowering therapy at hospital discharge (statins and/or other agents)
  • Subject who is 18 years or older
  • Subject or legally authorized representative who is willing and capable of providing informed consent, participating in all associated study activities
Exclusion Criteria
  • Subject unable to communicate via telephone for study interviewing
  • Subject with contraindication to statin therapy
  • Subject with any medical disorder that would interfere with completion or evaluation of clinical study results

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention group - Motivational InterviewMotivational InterviewPatients assigned to the intervention group will be given a leaflet entitled "Information leaflet about LDL Cholesterol" that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge.
Primary Outcome Measures
NameTimeMethod
Achievement of low-density lipoprotein cholesterol therapeutic goal, as specified by current practice guidelines (LDL-C <70 mg/dL or >50% reduction from baseline LDL-C)12 months after discharge from hospital
Secondary Outcome Measures
NameTimeMethod
Overall adherence to lipid-lowering regimen, reported as both a continuous and a binary outcome, by using the 4-item Morisky Medication-Taking Adherence Scale12 months after discharge from hospital

Trial Locations

Locations (1)

AHEPA University Hospital

🇬🇷

Thessaloniki, Greece

© Copyright 2025. All Rights Reserved by MedPath